Imexon - Heidelberg Pharma

Drug Profile

Imexon - Heidelberg Pharma

Alternative Names: AOP 99.0001; AOP-990001

Latest Information Update: 16 Mar 2010

Price : $50

At a glance

  • Originator Heidelberg Pharma
  • Class Antineoplastics; Antivirals; Hexanones; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Multiple myeloma

Most Recent Events

  • 31 Aug 2004 Phase-I/II clinical trials in Multiple myeloma in Russia (IV)
  • 31 Aug 2004 Phase-I/II clinical trials in Multiple myeloma in Austria (IV)
  • 31 Aug 2004 Phase-I/II clinical trials in Multiple myeloma in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top